Tiffany Rushen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tiffany Rushen has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Christina Kazzi
Department of Neuroscience, School of Translational Medicine Monash University Melbourne Victoria Australia
5 shared publications - Helmut Butzkueven
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia
5 shared publications - Mastura Monif
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia
5 shared publications Rubina Alpitsis
Department of Neuroscience, School of Translational Medicine Monash University Melbourne Victoria Australia
5 shared publications- Tracie Huey-Lin Tan
Department of Neuroscience, School of Translational Medicine Monash University Melbourne Victoria Australia
5 shared publications - Anneke van der Walt
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia
4 shared publications
Latest Publications
- 16 September 2026
- Published by Wiley in British Journal of Haematology
Patient‐reported symptom burden after chimeric antigen receptor T‐cell therapy
- 16 September 2026
- Published by Wiley in British Journal of Haematology
Patient‐reported symptom burden after chimeric antigen receptor T‐cell therapy
- Open Access
- 25 March 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 860.e1-860.e12
Cognitive Recovery Following Immune Effector Cell-Associated Neurotoxicity Syndrome in the First 6 Months after Chimeric Antigen Receptor T-Cell Therapy
- 25 March 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 860.e1-860.e12
Open AccessCognitive Recovery Following Immune Effector Cell-Associated Neurotoxicity Syndrome in the First 6 Months after Chimeric Antigen Receptor T-Cell Therapy
- 7 March 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 856.e1-856.e12
A Computerized Cognitive Test for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T-Cell Therapy Recipients: A Pilot Study
- 7 March 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 856.e1-856.e12
A Computerized Cognitive Test for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T-Cell Therapy Recipients: A Pilot Study
- Open Access
- 27 November 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (4) , 436-445
Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell Therapy
- 27 November 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (4) , 436-445
Open AccessRepeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell Therapy
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (4) , e200412
Acute and Long-Term Immune-Treatment Strategies in Anti-LGI1 Antibody–Mediated Encephalitis
Few studies have evaluated acute immunotherapy and relapse prevention strategies in patients with anti-leucine-rich glioma-inactivated 1 (LGI1) antibody (Ab)-mediated encephalitis. The objective of this study was to analyze the outcomes of acute and long-term immunotherapy strategies in this population. We undertook a multicenter cohort study of 55 patients with anti-LGI1 Ab-mediated encephalitis, either recruited prospectively or identified retrospectively from 10 Australian hospitals as part of the Australian Autoimmune Encephalitis Consortium. Clinical data were collected, including treatment durations of all relevant immunotherapies. Clinical outcomes that we examined included (1) time to first clinical relapse, (2) improvement on modified Rankin Scale (mRS), and (3) favorable binary composite clinical-functional outcome at 12 months. A favorable outcome was defined as fulfilling all three of mRS less than 3, a score of 1 or less in the memory dysfunction component of the Clinical Assessment Scale in Autoimmune Encephalitis, and absence of drug-resistant epilepsy. Rituximab, adjusted for concomitant use of other immunotherapies, was associated with increased time to first relapse (hazard ratio 0.10; 95% CI 0.001-0.85; p = 0.03). Intravenous pulsed methylprednisolone was associated with an improvement in mRS (OR 4.48; 95% CI 1.03-21.3; p = 0.048) and a favorable composite clinical-functional outcome (OR 4.96; 95% CI 1.07-27.2; p = 0.049) at 12 months. Rituximab may be effective at preventing relapses in patients with anti-LGI1 Ab-mediated encephalitis. Acute methylprednisolone treatment may be associated with favorable outcomes at 12 months. This study provides Class IV evidence that for patients with anti-LGI1 Ab-mediated encephalitis, rituximab prevents relapses and acute methylprednisolone is associated with favorable outcomes at 12 months.
- 1 July 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (4) , e200412
Open AccessAcute and Long-Term Immune-Treatment Strategies in Anti-LGI1 Antibody–Mediated Encephalitis
Few studies have evaluated acute immunotherapy and relapse prevention strategies in patients with anti-leucine-rich glioma-inactivated 1 (LGI1) antibody (Ab)-mediated encephalitis. The objective of this study was to analyze the outcomes of acute and long-term immunotherapy strategies in this population. We undertook a multicenter cohort study of 55 patients with anti-LGI1 Ab-mediated encephalitis, either recruited prospectively or identified retrospectively from 10 Australian hospitals as part of the Australian Autoimmune Encephalitis Consortium. Clinical data were collected, including treatment durations of all relevant immunotherapies. Clinical outcomes that we examined included (1) time to first clinical relapse, (2) improvement on modified Rankin Scale (mRS), and (3) favorable binary composite clinical-functional outcome at 12 months. A favorable outcome was defined as fulfilling all three of mRS less than 3, a score of 1 or less in the memory dysfunction component of the Clinical Assessment Scale in Autoimmune Encephalitis, and absence of drug-resistant epilepsy. Rituximab, adjusted for concomitant use of other immunotherapies, was associated with increased time to first relapse (hazard ratio 0.10; 95% CI 0.001-0.85; p = 0.03). Intravenous pulsed methylprednisolone was associated with an improvement in mRS (OR 4.48; 95% CI 1.03-21.3; p = 0.048) and a favorable composite clinical-functional outcome (OR 4.96; 95% CI 1.07-27.2; p = 0.049) at 12 months. Rituximab may be effective at preventing relapses in patients with anti-LGI1 Ab-mediated encephalitis. Acute methylprednisolone treatment may be associated with favorable outcomes at 12 months. This study provides Class IV evidence that for patients with anti-LGI1 Ab-mediated encephalitis, rituximab prevents relapses and acute methylprednisolone is associated with favorable outcomes at 12 months.